|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Amylin_Pharmaceuticals
gptkb:IFM_Therapeutics
gptkb:Medarex
gptkb:Turning_Point_Therapeutics
gptkb:Celgene
gptkb:MyoKardia
|
|
gptkbp:CEO
|
gptkb:Christopher_Boerner
|
|
gptkbp:competitor
|
gptkb:Pfizer
gptkb:Johnson_&_Johnson
gptkb:Merck_&_Co.
gptkb:Novartis
gptkb:Roche
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:division
|
immunology
oncology
hematology
cardiovascular
fibrosis
|
|
gptkbp:founded
|
1887
|
|
gptkbp:founder
|
gptkb:John_Ripley_Myers
gptkb:William_McLaren_Bristol
|
|
gptkbp:headquartersLocation
|
gptkb:New_York_City
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bristol Myers Squibb
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:keyPerson
|
gptkb:Giovanni_Caforio
|
|
gptkbp:legalForm
|
gptkb:public_company
|
|
gptkbp:listedOn
|
gptkb:Fortune_500
|
|
gptkbp:netIncome
|
$6.3 billion (2023)
|
|
gptkbp:notableEmployee
|
gptkb:Christopher_Boerner
gptkb:Giovanni_Caforio
|
|
gptkbp:numberOfEmployees
|
over 32,000
|
|
gptkbp:parentCompany
|
none
|
|
gptkbp:products
|
gptkb:Revlimid
gptkb:Eliquis
gptkb:Opdivo
gptkb:Orencia
gptkb:Sprycel
gptkb:Yervoy
gptkb:Abraxane
|
|
gptkbp:publiclyTraded
|
true
|
|
gptkbp:revenue
|
$45.0 billion (2023)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:NYSE
|
|
gptkbp:stockSymbol
|
gptkb:BMY
|
|
gptkbp:subsidiary
|
gptkb:Amylin_Pharmaceuticals
gptkb:Medarex
gptkb:Celgene
gptkb:MyoKardia
|
|
gptkbp:website
|
https://www.bms.com/
|
|
gptkbp:bfsParent
|
gptkb:gene_therapy
gptkb:AstraZeneca
gptkb:Juno_Therapeutics
gptkb:Karuna_Therapeutics
gptkb:Vedanta_Biosciences
gptkb:NOVN
|
|
gptkbp:bfsLayer
|
5
|